Steven Schuster, MD
Hematology & Oncology · Fort Collins, CONPI 1467664136
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $269,742 of the $297,887 with a category attached, or 90.6%. It is spread thinly across 18 manufacturers, the largest accounting for just 23.9%. Among hematology & oncology clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 251 payments — averaging $1186.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pharmacyclics LLC, An Abbvie Company$71K
- Johnson & Johnson$62K
- Genentech USA, Inc.$51K
- AbbVie$47K
- Karyopharm Therapeutics Inc.$43K
- Genmab U.S., Inc.$22K
- plus $2K from 12 others
Across 738 payments — averaging $11,051 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$4.6M
- Seagen Inc.$1.4M
- Novartis$520K
- Eli Lilly$474K
- Janssen Research & Development, LLC$389K
- Incyte Corporation$120K
- plus $666K from 12 others
What the payments were for
- Consulting fees$4,1701%
- Speaking & faculty fees$269,74291%
- Travel & lodging$18,8346%
- Food & beverage$5,0262%
- Education$1160%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | 67 | $71,079 |
| Johnson & Johnson(2 entities) | 51 | $61,667 |
| Genentech USA, Inc. | 39 | $50,732 |
| AbbVie | 34 | $47,222 |
| Karyopharm Therapeutics Inc. | 31 | $43,129 |
| Genmab U.S., Inc. | 14 | $21,599 |
| ADC Therapeutics America, Inc. | 1 | $1,400 |
| Bristol Myers Squibb | 1 | $750 |
| Jazz Pharmaceuticals Inc. | 1 | $103 |
| Pfizer | 3 | $44 |
| Novartis | 2 | $32 |
| Novo Nordisk | 1 | $26 |
| Adaptive Biotechnologies Corporation | 1 | $22 |
| Mirati Therapeutics, Inc. | 1 | $21 |
| Gilead | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Myovant Sciences Inc. | 1 | $13 |
| Incyte Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$297,887 in reported general payments places this provider in the 95th percentile of 169 hematology & oncology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 66 | $852,636 |
| VenclextaVenetoclax | 91 | $848,437 |
| PomalystPomalidomide | 42 | $693,492 |
| ImbruvicaIbrutinib | 35 | $667,440 |
| JakafiRuxolitinib Phosphate | 43 | $626,184 |
| CalquenceAcalabrutinib Maleate | 41 | $545,078 |
| RevlimidLenalidomide | 20 | $379,252 |
| TasignaNilotinib Hcl | 13 | $214,297 |
| BrukinsaZanubrutinib | 13 | $193,225 |
| GleevecImatinib Mesylate | 13 | $95,059 |
| XareltoRivaroxaban | 31 | $36,697 |
| EliquisApixaban | 20 | $19,196 |
| Acyclovir | 214 | $3,591 |
| Abiraterone Acetate | 11 | $1,535 |
| CholestyramineCholestyramine (With Sugar) | 19 | $1,427 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVenclexta | $47,222 | $848,43791 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $16 | $693,49242 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $71,079 | $667,44035 claims |
| Incyte CorporationJakafi | $12 | $626,18443 claims |
| Bristol Myers SquibbRevlimid | $750 | $379,25220 claims |
| NovartisTasigna, Gleevec | $32 | $309,35526 claims |
| Johnson & JohnsonXarelto | $61,667 | $36,69731 claims |
| PfizerEliquis | $44 | $19,19620 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 169 hematology & oncology providers in Colorado.
Other hematology & oncology in Fort Collins
- Amy SchmidtDenver$2.8M
- Yousuf GaffarDenver$963K
- John BurkeAurora$321K
- Manojkumar BupathiLittleton$312K
- Douglas ReznickAurora$294K
- Daniel PollyeaAurora$274K
- Robert RifkinDenver$270K
- Christopher BentonEnglewood$249K
- Mabel MardonesDenver$149K
- Peter ForsbergDenver$147K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.